Triplet therapy for all comers in the CLL-BAG trial

The role of patient advocates in trial design, participation

Disruption of BAFF-BCR crosstalk in CLL

Interim analysis of the JULIET study

ZUMA 1: CD19 CAR T cells for refractory NHL

400mg imatinib as good as 800mg for 10 year CML survival

Carfilzomib combinations in ENDEAVOR and FORTE

Deep molecular response to gilteritinib in CHRYSALIS trial

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Diverse T lymphocyte population fights leukaemia more effectively

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL

Improving outcomes for oestrogen receptor positive breast cancer